Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of “Hold” by Analysts
01:28am, Thursday, 29'th Jan 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been given a consensus rating of "Hold" by the six analysts that are currently covering the company, MarketBeat reports. One in
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
08:00am, Wednesday, 28'th Jan 2026
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the indust
Hussman Strategic Advisors Inc. Makes New Investment in Pacira BioSciences, Inc. $PCRX
05:52am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. purchased a new stake in Pacira BioSciences, Inc. (NASDAQ: PCRX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Secu
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:06pm, Wednesday, 14'th Jan 2026
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
11:20am, Wednesday, 14'th Jan 2026
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
08:00am, Tuesday, 13'th Jan 2026
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
11:17am, Monday, 12'th Jan 2026
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down – Time to Sell?
03:26am, Sunday, 11'th Jan 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $26.02, but opened at $24.64. Pacira BioSciences
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
04:01pm, Thursday, 08'th Jan 2026
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
08:00am, Wednesday, 07'th Jan 2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
/PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 6.83% of the outstanding
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) by 51.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The
5 Biotech Stocks to Watch for Potential Upside
03:21pm, Wednesday, 17'th Dec 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
11:25am, Wednesday, 03'rd Dec 2025
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 03'rd Dec 2025
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
